SynthesisTissue engineering and regenerative medicine2026
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.
Synthesis in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough traumatic brain injury (TBI) is a significant cause of morbidity and mortality worldwide, there have been few significant therapeutic advances in recent years. Preclinical studies have explored the potential of adipose-derived stem cells (ADSCs) to improve neural function and reduce brain damage in animal models following TBI. This systematic review aims to assess and synthesize the current evidence on the efficacy of ADSCs in animal models with induced TBI.
methodsFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Scopus, PubMed, Web of Science, and Cochrane Library from inception to July 7, 2024, for original, English-language studies on animal models of induced TBI treated with ADSCs. We excluded in vitro, in silico, studies involving humans, and conference abstracts. Risk of bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool.
resultsTwenty-two studies met the inclusion criteria. The most common routes of ADSC administration were intravenous and intracerebral injections, typically given within 24 h of induced TBI. Histological and neuroimaging assessments showed reduced tissue swelling and interstitial fluid accumulation in ADSC-treated animals, indicating decreased brain vasogenic edema. ADSC treatment also reduced neuroinflammation markers, suggesting lower activation of astrocytes and microglia around the injury site associated with M2 microglial phenotype polarization. Enhanced neurogenesis was observed, particularly in the hippocampus, with markers like bromodeoxyuridine (BrdU) and neuronal nuclei (NeuN) indicating improved neuron formation. Consistent cognitive and motor improvements were also noted, with treated animals showing shorter escape times and path lengths in spatial memory tests (e.g., Morris Water Maze) and better motor coordination in beam tests.
conclusionThe available pre-clinical in vivo evidence indicates that ADSC-based therapies have the potential to mitigate neuroinflammation, reduce brain edema, enhance neurogenesis, and improve functional outcomes following induced TBI. Clinical studies are warranted to investigate the use of ADSCs in the treatment of TBI in humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.